Psilocybin-assisted group therapy appears safe and feasible for treating depression in cancer patients. In an open-label pilot trial, twelve participants with a depressive disorder received one high-dose (25 mg) psilocybin session within a three-week group program. Depression scores on the HAM-D scale decreased substantially from an average of 21.5 at baseline to 10.09 at two weeks and 14.83 at six months. Six of twelve participants met remission criteria (HAM-D below 7) at two weeks, and no serious adverse events occurred. The group format may reduce therapist time while maintaining possible efficacy, warranting further study.
Adding a single 25 mg dose of psilocybin to an 8-week mindfulness-based stress reduction (MBSR) program reduced depression and burnout symptoms more than MBSR alone in frontline physicians and nurses who worked during the COVID-19 pandemic. In a randomized trial with 25 participants, those receiving psilocybin-assisted therapy plus MBSR showed larger decreases in depressive symptoms at two weeks and six months, and greater improvements in burnout, demoralization, and connectedness. No serious adverse events occurred; only mild to moderate side effects were reported. The findings suggest that combining psilocybin with mindfulness training may be a promising treatment for depression and burnout in healthcare workers.
Clinical trials of classical psychedelics like psilocybin for mental health conditions face unique challenges that may persist if these treatments enter clinical practice. Four categories of challenges with trial participants are identified: treatment nonresponse, expectancy effects and functional unblinding, post-session psychological difficulties, and contagion effects. Management strategies for study teams to mitigate these risks are described. The National Network of Depression Centers and similar organizations can guide best practices to responsibly advance this promising field.